Scrip Asks…What Does 2023 Hold For Biopharma? Part 3: Global Headwinds
Tough Times Call For Resilience, Flexibility And Collaboration
Executive Summary
Headwinds of political instability, violent conflict, inflation and recession accompany us into 2023. Scrip surveyed industry leaders on the impacts for biopharma.
You may also be interested in...
Top-Selling Drugs 2022: Strong Growth In Blockbuster Ranks
COVID-19 products contributed almost a third to the global revenues from the top 20 best-selling drugs in 2022. However, strong growth was also seen for drugs across categories from immunology and cancer to HIV and cardiometabolic.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 10: Diversity, Equity And Inclusion
The acceleration of efforts to increase diversity among clinical trial subjects is expected to continue in 2023. Furthermore, many executives hope for greater inclusivity within companies, from new recruits to leadership.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 9: The Natural Environment
Improving human health is the raison d’etre of the biopharma sector. But what can the industry do to safeguard and improve the health of Planet Earth? Executives shared their thoughts with Scrip.